Nippon India Pharma Fund
Nippon India Mutual Fund · Sectoral/Thematic · Direct plan, growth option
NAV (₹), 2 Oct 2026
628.4076
1-day change
-0.29%
1Y return
12.4%
3Y CAGR
17.6%
5Y CAGR
13.5%
Max drawdown, 5Y
−19.1%
NAV history month-end NAV, ₹ · 2 Jan 2013 to 1 Oct 2026
Returns vs Sectoral/Thematic median (253 schemes) and “Healthcare & pharma” median (19)
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | -3.0% | -5.4% | -3.1% |
| 3 months | 0.8% | -2.8% | 3.0% |
| 6 months | 14.9% | 8.9% | 21.7% |
| Year to date | 10.3% | -2.0% | 17.3% |
| 1 year | 12.4% | 1.4% | 17.5% |
| 3 years (CAGR) | 17.6% | 13.0% | 20.8% |
| 5 years (CAGR) | 13.5% | 12.0% | 15.3% |
| 7 years (CAGR) | 23.0% | 17.0% | 24.9% |
| 10 years (CAGR) | 15.5% | 14.6% | 14.7% |
| Since first NAV (CAGR) | 17.3% | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
Rolling returns every business-day start date
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 13.2% | 11.8% |
| 3Y rolling median | 19.9% | 17.5% |
| 3Y rolling worst | -1.3% | 3.0% |
| 3Y periods positive | 99% | 100% |
| 3Y periods ahead of benchmark | 70% | 84% |
| 5Y rolling median | 16.7% | 15.6% |
| 5Y rolling worst | 0.0% | 1.8% |
| 5Y periods ahead of benchmark | 72% | 91% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
Risk 36 months, monthly returns, Rf 6.5%
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 14.8% | 16.7% |
| Sharpe ratio | 0.84 | 0.42 |
| Sortino ratio | 1.39 | 0.63 |
| Beta | 0.69 | 0.96 |
| Alpha (ann.) | 10.1% | 3.7% |
| Upside capture | 106.83 | 106.94 |
| Downside capture | 64.35 | 95.17 |
Drawdowns peak-to-trough falls in NAV
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −24.0% | −23.1% |
| Maximum drawdown, last 10Y | −21.2% | −38.3% |
| Maximum drawdown, last 5Y | −19.1% | −22.3% |
| Current drawdown | −3.9% | −8.3% |
| Recovery time of worst fall | 445 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
Cost, size and riskometer as disclosed to AMFI
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Direct plan | n/a | 1.23% |
| AUM, whole scheme (₹ crore) | 9,166 | 1,272 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
Official benchmark and category consistency
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 13.9% | 16.8% TRI |
| Return, 3 years (AMFI) | 17.7% | 21.3% TRI |
| Return, 5 years (AMFI) | 13.7% | 14.6% TRI |
| Month-ends above category median (3Y CAGR) | 53% | 53% median |
| Month-ends in category top quartile (3Y) | 36% | 24% median |
| 7Y rolling CAGR, median (monthly windows) | 18.0% | 15.2% median |
Official benchmark: BSE Healthcare TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Sectoral/Thematic Direct plans; how it is calculated.
Calendar-year returns NAV change from 31 Dec to 31 Dec
| Year | Scheme | Nifty 500 proxy | Difference |
|---|---|---|---|
| 2026 YTD | 10.3% | -7.8% | +18.1% |
| 2025 | -2.5% | 7.7% | −10.1% |
| 2024 | 35.3% | 15.6% | +19.6% |
| 2023 | 40.4% | 26.5% | +13.8% |
| 2022 | -9.1% | 3.8% | −12.9% |
| 2021 | 25.1% | 30.6% | −5.5% |
| 2020 | 67.9% | 17.2% | +50.7% |
| 2019 | 2.5% | n/a | – |
| 2018 | 4.6% | n/a | – |
| 2017 | 8.6% | n/a | – |
Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.
Monthly SIP of ₹10,000 first business day of each month, ending 2 Oct 2026
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,28,835 | 13.9% |
| 3 years | ₹3,60,000 | ₹4,29,025 | 11.7% |
| 5 years | ₹6,00,000 | ₹9,08,608 | 16.6% |
| 10 years | ₹12,00,000 | ₹31,47,990 | 18.3% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
Scheme facts
Category: Sectoral/Thematic
Plan / option: Direct · Growth
AMFI scheme code: 118759
ISIN: INF204K01I50
First NAV in MFIC data: 2 Jan 2013
History: 13.7 years
Expense ratio, AUM, portfolio: see the scheme's factsheet
Schemes that behaved similarly correlation of monthly returns, last 5 years
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| Aditya Birla Sun Life Pharma and Healthcare Fund | Sectoral/Thematic | 0.98 | 20.1% |
| Tata India Pharma & Healthcare Fund | Sectoral/Thematic | 0.97 | 18.3% |
| Mirae Asset Healthcare Fund | Sectoral/Thematic | 0.97 | 21.8% |
| UTI - Healthcare Fund | Sectoral/Thematic | 0.97 | 22.5% |
| HDFC Pharma and Healthcare Fund | Sectoral/Thematic | 0.96 | 30.2% |
| ICICI Prudential Healthcare Fund | Sectoral/Thematic | 0.96 | 21.1% |
Questions about Nippon India Pharma Fund
- What is the latest NAV of Nippon India Pharma Fund?
- The NAV of the Direct plan (growth option) was ₹628.4076 on 2 Oct 2026, as published by AMFI.
- Which category is Nippon India Pharma Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 253 Sectoral/Thematic schemes (Direct plans).
- What returns has Nippon India Pharma Fund delivered?
- Over one year the NAV changed by 12.4%. The 3-year CAGR is 17.6% (category median 13.0%) and the 5-year CAGR is 13.5% (category median 12.0%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 19.9%, the lowest was -1.3%, and 99% of 3-year periods ended with a gain. It was ahead of Nifty 500 (index-fund proxy) in 70% of those periods.
- What was the largest fall in Nippon India Pharma Fund's NAV?
- The largest peak-to-trough fall in its available history was 24.0%; within the last five years it was 19.1% (category median 22.3%).
- How volatile is Nippon India Pharma Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 14.8%, which is below the Sectoral/Thematic category median of 16.7%.
- What would a monthly SIP in Nippon India Pharma Fund have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 5 years (60 instalments, ₹6,00,000 invested) would have been worth about ₹9,08,608 on 2 Oct 2026, an annualised return (XIRR) of 16.6%. This uses the Direct plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- How large is Nippon India Pharma Fund?
- Assets under management of the whole scheme were ₹9,166 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of Nippon India Pharma Fund?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the benchmark of Nippon India Pharma Fund and how has it compared?
- Its official benchmark is the BSE Healthcare TRI. Over 3 years AMFI reports a return of 17.7% for this plan against 21.3% for the benchmark total return index; over 5 years 13.7% against 14.6%. Past performance does not indicate future results.
- How often has Nippon India Pharma Fund beaten its category?
- At 53% of the 120 month-ends compared over the last 10 years, its 3-year return was above the median of Sectoral/Thematic schemes (Direct plans); it was in the top quarter at 36% of them. A typical scheme would show about 50%.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 12.4% and the Regular plan's by 11.4%. The Regular plan includes the services of a distributor.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow Nippon India Pharma Fund by email
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.
Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 2 Oct 2026. Category medians use Direct plans in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.